SEP 16, 2014 12:00 AM PDT

Interfering with Interferon

Virus-killing molecules may need all their skills, including inflammation, to fight HIV infection. Using the body's natural virus killers to prevent and treat HIV infection has been problematic until now because of the strong inflammatory response these molecules can stimulate as they get rid of the invaders. Now, collaborative research conducted by scientists at the Weizmann Institute and the National Institutes of Health (NIH) have demonstrated how suppressing the activity of these molecules - interferons - around the time of infection could have long-term implications for the course of the disease. Their research appeared in Nature.

Interferons, named for their ability to "interfere" with viral replication, protect us against disease, but they are also the source of inflammation when we are sick. Today, interferons are used to treat such viral diseases as hepatitis. But in HIV, it has been thought that the inflammation and other side effects could be too harmful and the danger of a "runaway" immune response too great. Prof. Gideon Schreiber of Weizmann's Department of Biological Chemistry and his team, including postdoctoral fellow Dr. Doron Levin and former postdoc Dr. Ganit Yarden, had, in previous research, designed an antagonist molecule that is able to block some of the activities of interferons while still allowing them to proceed to act against viruses.

Their original motivation, said Prof. Schreiber, was to better understand the mechanisms of different versions of the interferon molecule. This research revealed that the activity of each interferon is tuned to specific cells and viruses. The molecule they had created, according to Prof. Schreiber, "was not a true ‘antagonist' in the biological sense: Instead of blocking all IFN [interferon] activity, it was able to target the mechanisms leading to the prevention of replication and modulation of the immune system, leaving the antiviral activity mostly intact."

Next, Prof. Schreiber and his group teamed up with Dr. Netanya Sandler and Prof. Daniel Douek at the NIH to understand what happens when full-out interferon activity is tampered with in HIV. The research was done on simian immunodeficiency virus (SIV) - the animal equivalent to HIV. Their results show that the actions blocked by the molecule may have important functions, even if they appear to be "detrimental." The team administered an antagonist, blocking a particular interferon (Type 1 IFN) for the first four weeks after infection. Even after this short period, they found that the natural immune system activities did not recover and compensate to the level they otherwise would have, and this led to a progression of the disease.

Prof. Schreiber explained, "These results clearly demonstrate the importance of an early, general IFN response in fighting HIV infection, and removing the ‘harmful' IFN functions even for just a short period at the onset of infection can have devastating and permanent consequences in shaping the course of disease." Taken together, these findings suggest that not only the type of treatment, but also the timing of IFN administration needs to be considered in the management and prevention of disease. Prof. Gideon Schreiber's research is supported by the Dana and Yossie Hollander Center for Structural Proteomics, which he heads, and the R Baby Foundation.
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
SEP 17, 2019
Immunology
SEP 17, 2019
Vaccination Helps Prevent Diabetes
A drop in the number of young children diagnosed with type 1 diabetes could be associated with the introduction of routine rotavirus vaccination....
SEP 17, 2019
Immunology
SEP 17, 2019
Fecal Transplant improves ASD
Our understanding of the brain-gut connection is increasing by the day. Individuals with autism spectrum disorder (ASD) also experience gastrointestinal sy...
SEP 17, 2019
Immunology
SEP 17, 2019
The C-word. Michael Kinch's new book and the future of Cancer Treatment
The C-word. Dare we say it? Is a cure for cancer within reach?   Professor Michael Kinch https://publichealth.wustl.edu/scholars/michael-s-kinch/ of W...
SEP 17, 2019
Health & Medicine
SEP 17, 2019
Balanced Gut Bacteria May Relieve Anxiety Symptoms
The Anxiety and Depression Association of America estimates that 18% of adults in the United States suffer from an anxiety disorder. According to the World...
SEP 17, 2019
Cancer
SEP 17, 2019
How cancer tricks our immune systems
Research published yesterday in Nature details the finding of a new “Don’t eat me” signal that cancers use to hide from the body’s ...
SEP 17, 2019
Cardiology
SEP 17, 2019
Better Sleep, Brought To You By Exercise
Regular difficulty falling or staying asleep, called chronic insomnia, is the most common sleep disorder among adults. In the search for better, more restf...
Loading Comments...